## M Saeed Sheikh

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6729983/publications.pdf

Version: 2024-02-01

471509 454955 1,149 33 17 30 citations h-index g-index papers 33 33 33 1774 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	The emerging CDK4/6 inhibitor for breast cancer treatment Molecular and Cellular Pharmacology, 2021, 13, 9-12.	1.7	O
2	ECRG2, a novel transcriptional target of p53, modulates cancer cell sensitivity to DNA damage. Cell Death and Disease, 2020, $11$ , $543$ .	6.3	5
3	Quinovic acid purified from medicinal plant Fagonia indica mediates anticancer effects via death receptor 5. Molecular and Cellular Biochemistry, 2020, 474, 159-169.	3.1	5
4	CHTM1 regulates cancer cell sensitivity to metabolic stress via p38-AIF1 pathway. Journal of Experimental and Clinical Cancer Research, 2019, 38, 271.	8.6	2
5	Toxicology of Trastuzumab: An Insight into Mechanisms of Cardiotoxicity. Current Cancer Drug Targets, 2019, 19, 400-407.	1.6	17
6	CHTM1, a novel metabolic marker deregulated in human malignancies. Oncogene, 2018, 37, 2052-2066.	5.9	5
7	Monoglyceride lipase gene knockout in mice leads to increased incidence of lung adenocarcinoma. Cell Death and Disease, 2018, 9, 36.	6.3	16
8	Regulation of p53 oligomerization by Ras superfamily protein RBEL1A. Genes and Cancer, 2015, 6, 307-316.	1.9	7
9	RNA-binding Protein, GADD45-alpha, p27, p53 and Genotoxic Stress Response in Relation to Chemoresistance in Cancer. Molecular and Cellular Pharmacology, 2015, 7, 41-45.	1.7	2
10	Melanoma: Molecular Pathogenesis and Therapeutic Management. Molecular and Cellular Pharmacology, 2014, 6, 228.	1.7	72
11	Negative regulation of p53 by Ras superfamily protein RBEL1A. Journal of Cell Science, 2013, 126, 2436-45.	2.0	27
12	Metabolic Stress and Disorders Related to Alterations in Mitochondrial Fission or Fusion. Molecular and Cellular Pharmacology, 2013, 5, 109-133.	1.7	45
13	CHCM1/CHCHD6, Novel Mitochondrial Protein Linked to Regulation of Mitofilin and Mitochondrial Cristae Morphology. Journal of Biological Chemistry, 2012, 287, 7411-7426.	3.4	108
14	Dihydroartemisinin upregulates death receptor 5 expression and cooperates with TRAIL to induce apoptosis in human prostate cancer cells. Cancer Biology and Therapy, 2010, 9, 819-824.	3.4	77
15	The promise of paclitaxel-peptide conjugates for MMP-2-targeted drug delivery. Cancer Biology and Therapy, 2010, 9, 204-205.	3.4	4
16	Identification of Pirh2D, an Additional Novel Isoform of Pirh2 Ubiquitin Ligase. Molecular and Cellular Pharmacology, 2010, 2, 21-23.	1.7	4
17	Identification and Characterization of Two Novel Isoforms of Pirh2 Ubiquitin Ligase That Negatively Regulate p53 Independent of RING Finger Domains. Journal of Biological Chemistry, 2009, 284, 21955-21970.	3.4	20
18	Sulindac Sulfide Differentially Induces Apoptosis in Smac-Proficient and -Deficient Human Colon Cancer Cells. Molecular and Cellular Pharmacology, 2009, 1, 92-97.	1.7	8

#	Article	IF	Citations
19	Energy Generating Pathways and the Tumor Suppressor p53. , 2009, , 131-150.		O
20	TRAIL death receptors and cancer therapeutics. Toxicology and Applied Pharmacology, 2007, 224, 284-289.	2.8	55
21	Cyclooxygenase-2 interacts with p53 and interferes with p53-dependent transcription and apoptosis. Oncogene, 2005, 24, 1634-1640.	5.9	69
22	Genotoxic and endoplasmic reticulum stresses differentially regulate TRB3 expression. Cancer Biology and Therapy, 2005, 4, 1063-1067.	3.4	52
23	Death Receptors as Targets of Cancer Therapeutics. Current Cancer Drug Targets, 2004, 4, 97-104.	1.6	48
24	The p53 paddy wagon: COP1, Pirh2, and MDM2 are found resisting apoptosis and growth arrest. Cancer Biology and Therapy, 2004, 3, 721-725.	3.4	41
25	Myc tagging along the TRAIL to death receptor 5. Cell Cycle, 2004, 3, 920-2.	2.6	2
26	Cloning and characterization of a novel gene PDRG that is differentially regulated by p53 and ultraviolet radiation. Oncogene, 2003, 22, 7247-7257.	5.9	47
27	The FADD is going nuclear. Cell Cycle, 2003, 2, 346-7.	2.6	15
28	Death receptor activation complexes: it takes two to activate TNF receptor 1. Cell Cycle, 2003, 2, 550-2.	2.6	53
29	Radiosensitivity with Par-4 Expression in Prostate Cancer. Cancer Biology and Therapy, 2002, 1, 161-162.	3.4	25
30	Endoplasmic reticulum calcium pool depletion-induced apoptosis is coupled with activation of the death receptor 5 pathway. Oncogene, 2002, 21, 2623-2633.	5.9	93
31	Apo2L/TRAIL differentially modulates the apoptotic effects of sulindac and a COX-2 selective non-steroidal anti-inflammatory agent in Bax-deficient cells. Oncogene, 2002, 21, 6032-6040.	5.9	58
32	Role of p53 family members in apoptosis. Journal of Cellular Physiology, 2000, 182, 171-181.	4.1	166
33	Role of p53 family members in apoptosis. , 0, .		1